Why the study?
Does insulin action on fatty acid and carbohydrate metabolism differ in patients with Familial Combined Hyperlipidemia compared to healthy controls?
Population
Patients with Familial Combined Hyperlipidemia (FCHL) and healthy control subjects
Comparison
Two-step euglycemic, hyperinsulinemic clamp vs Healthy control subjects
Design
Case-control
Authors
Loading...
FCHL patients show impaired insulin-mediated NEFA suppression; hypothesis-generating for primary metabolic defects driving dyslipidemia.
Does insulin action on fatty acid and carbohydrate metabolism differ in patients with Familial Combined Hyperlipidemia compared to healthy controls?
Patients with Familial Combined Hyperlipidemia exhibit a primary defect in insulin-mediated suppression of nonesterified fatty acids that is independent of upper-body fat, potentially contributing to lipoprotein abnormalities.
Aitman et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: